| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2021: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2020: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2018: ¥11,570,000 (Direct Cost: ¥8,900,000、Indirect Cost: ¥2,670,000)
|
|---|
| Outline of Final Research Achievements |
We focused on the polyketides produced by actinomycetes and analyzed their biosynthesis. Twenty gene disruption strains were generated based on the yorpyrazone producer strain, and their metabolism was analyzed. The results showed that the biosynthetic intermediate of yoropyrazone is a griseusin derivative. Furthermore, we succeeded in reconstituting part of the biosynthesis of griseusin derivatives in vitro. We also analyzed a part of the biosynthetic pathway of fogacin in vitro. We also worked on the X-ray crystallographic analysis of a particularly interesting enzyme among them. We also analyzed how polyketide synthase regulates protein-protein interactions and efficiently produces secondary metabolites, and elucidated some of the mechanisms.
|
